𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status

✍ Scribed by Wolfgang J. Köstler; Thomas Brodowicz; Gernot Hudelist; Margaretha Rudas; Reinhard Horvat; Günther G. Steger; Christian F. Singer; Johannes Attems; Werner Rabitsch; Negar Fakhrai; Katarzyna Elandt; Christoph Wiltschke; Michael Hejna; Christoph C. Zielinski

Publisher
Springer-Verlag
Year
2005
Tongue
English
Weight
262 KB
Volume
131
Category
Article
ISSN
1432-1335

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Her-2/neu and EGFR tyrosine kinase activ
Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer
✍ Gernot Hudelist; Wolfgang J. Köstler; Klaus Czerwenka; Ernst Kubista; Johannes A 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 372 KB 👁 2 views

## Abstract Her‐2/__neu__ overexpression in human breast cancer leads to an aggressive biological behavior and poor prognosis. Although the anti‐Her‐2/__neu__ antibody trastuzumab (Herceptin®) has become a valuable therapeutic option for patients with Her‐2/__neu__‐overexpressing breast cancer, man

C-Met overexpression in node-positive br
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu
✍ Ernst Lengyel; Dieter Prechtel; James H. Resau; Katja Gauger; Anita Welk; Kristi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 296 KB

Receptor tyrosine kinases play an important role in malignant transformation of epithelial cells by activating signal transduction pathways important for proliferation, invasion and metastasis. In a pilot study (n ‫؍‬ 40), we evaluated expression of the c-Met and Her2/neu receptor tyrosine kinases a